STOCKSCREENR
Log In

AKTX

NASDAQ

Akari Therapeutics, Plc

$0.22+0.01(+4.35%)Mkt Cap: $3.86K

Key Stats

Market Cap

$3.86K

P/E Ratio

-0.08

EPS

$-2.58

Dividend Yield

0.00%

52-Week Range

$0.20 — $1.73

Volume

826.87K

Avg Volume

456.40K

Beta

0.34

Valuation

P/E (TTM)

-0.08

Forward P/E

—

PEG Ratio

0.00

P/S (TTM)

0.00

P/B (TTM)

0.00

P/FCF

—

EV/EBITDA

—

EV/Sales

—

Financial Health

ROE (TTM)

-0.68%

ROA (TTM)

-0.35%

ROIC

—

Gross Margin

0.00%

Operating Margin

0.00%

Net Margin

—

Debt/Equity

0.09

Current Ratio

0.19

Growth

EPS Growth (YoY)

—

Revenue Growth (YoY)

—

EPS Growth (3Y)

-2.16%

EPS Growth (5Y)

-1.13%

Sales Growth (3Y)

+0.00%

Sales Growth (5Y)

+0.00%

EPS Est (This Year)

$-0.19

EPS Est (Next Year)

$-0.22

Dividends

Dividend Yield

—

Annual Dividend

—

Payout Ratio

—

Frequency

—

Ex-Dividend Date

—

Cash/Share

$7604.91

Analyst Consensus

Ownership

Institutional %

—

Inst. Net Change

—

Insider Net Shares (90d)

—

Outstanding Shares

17.87K

Float

16.24K

Free Float %

90.89%

About

Sector

Healthcare

Industry

Biotechnology

Country

GB

Exchange

NASDAQ

IPO Date

2014-01-06

Employees

8

CEO

Abizer Gaslightwala

Index Membership

—

Website

https://www.akaritx.com

Akari Therapeutics, Plc (AKTX) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $3.86K, a P/E ratio of -0.08, AKTX is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare AKTX against other stocks using dozens of fundamental and technical filters.

Similar Stocks

SYRS

Syros Pharmaceuticals, Inc.

$0.00

-75.00%

$5.37K

BCTXW

BriaCell Therapeutics Corp.

$0.00

+0.00%

$1.70K

PBMWW

Psyence Biomedical Ltd. Warrant

$0.02

+0.00%

$1.28K

VRPX

Virpax Pharmaceuticals, Inc.

$0.01

+0.00%

$13.67K

SLXNW

Silexion Therapeutics Ltd.

$0.02

+0.59%

$9.59K

ADTX

Aditxt, Inc.

$1.48

-8.64%

$3.98K

Frequently Asked Questions

What is Akari Therapeutics, Plc's P/E ratio?

Akari Therapeutics, Plc (AKTX) has a trailing twelve-month (TTM) P/E ratio of -0.08. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does Akari Therapeutics, Plc pay a dividend?

No, Akari Therapeutics, Plc (AKTX) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is Akari Therapeutics, Plc's market cap?

Akari Therapeutics, Plc (AKTX) has a market capitalization of $3,860, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.